Navigation Links
Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
Date:3/27/2008

CHICAGO, IL MARCH 27, 2008 The Cardiovascular Research Foundation (CRF) will present results of the largest meta-analysis to date comparing mortality rates for drug-eluting stents (DES) versus bare metal stents (BMS) at the Drug-Eluting Stent Revolution VII meeting tomorrow evening in Chicago.

The analysiswhich includes approximately 180,000 patients from 52 studieswas performed by a team of researchers led by Ajay J. Kirtane, MD, Assistant Professor of Clinical Medicine and an interventional cardiologist at NewYork-Presbyterian Hospital/Columbia University Medical Center, and Gregg W. Stone, MD, Chairman of CRF and Professor of Medicine at Columbia University Medical Center and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital.

Drs. Kirtane and Stone conducted two parallel meta-analyses examining DES vs. BMS use in both randomized, controlled trials and in observational registry analyses. The overall analysis represents the largest systematic overview of real-world (comprising both on-label and off-label) DES use to date and incorporates an updated overview of both the published literature as well as the most recent data from several unpublished studies presented in the last year.

The findings from these parallel studies are striking, said Dr. Stone.

The meta-analysis of 22 randomized trials included more than 9000 patients with recent follow-up from previously published trials. According to the results, DES resulted in small non-significant reductions in death and MI, with a greater than 50% decrease in subsequent TVR procedures, said Dr. Stone, adding that these findings are consistent with both on-label and off-label use of DES.

And in the 30-study registry meta-analysis (involving more than 170,000 real-world patients), DES resulted in significant 20% and 11% reductions in death and MI, respectively, with a similar reduction in TVR (47%) as in the randomized trials, even after adjustment for confounding variables, said Dr. Stone. These data are reassuring that DES are safe and effective for a wide-range of patients that are able to take dual antiplatelet therapy for at least one year.

The findings were consistent and robust across a variety of study designs and even in trials incorporating longer-term follow-up; trials that were included were required to follow patients for at least one year.

Dr. Kirtane remarked that these findings should help to reassure patients and physicians about the safety of DES in off-label use.

Even with the stated limitations of registry data, the bottom line from both randomized trials and observational analyses is consistent: we can reduce the need for repeat procedures and we clearly are not harming patients with DES, he added.


'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
212-851-9187
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. An invitation to Europes largest forum on breast cancer
2. Spartan Stores Becomes Largest U.S. Supermarket Chain to Receive NSF Shop Fresh(TM) Certification
3. CVS, Americas Largest Pharmacy Chain, Pays Nearly $37 Million to Settle Federal and State Generic Drug Switching Charges
4. Grassini & Wrinkle Law Firm Are Awarded Largest PI Verdict in Ventura County History
5. Medco Breaks Ground For Worlds Largest Automated Pharmacy
6. Cardiac Science Delivers Largest Order of Electrocardiograph Systems in Company History
7. AMSA Annual Convention: Largest Gathering of Medical Students Celebrates 58 Years of Student Activism
8. McGraw-Hill Professional Enters Partnership with American College of Physicians, the Worlds Largest Internal Medicine Organization
9. Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists
10. Crdentia Selected by Leading Staffing Vendor to Provide Health Care Staffing Services to One of the Largest Hospital Chains in the U.S.
11. $30.3 Million Jury Verdict Believed to Be New Jerseys Largest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group LLC is pleased ... professionals throughout the country. The Guard was specifically designed to handle each element ... training, regulatory updates, and compliance coaching. , In addition to meeting the compliance ...
(Date:2/10/2016)... SAN FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... category: Best Water Brand. There were three leading bottled water brand owners that topped ... edge services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, ...
(Date:2/10/2016)... ... 2016 , ... Ongoing news of the ravages of traumatic brain injury (TBI) ... survey that takes a closer look at cases of TBI being managed by their ... TBI among the aging population, and identifies the challenges associated with their care. , ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Gout is ... and brings pain that is often severe, with intense swelling and redness. It is ... eight million people, but older adults are the most susceptible, according to the February ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association ... inspirational speaker Jan Fox will serve as keynote speaker at the organization’s 2016 ... with tools to more effectively communicate with their own organizational staff and leadership. ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 Urologix, the market leader for in-office ... Prostatic Hyperplasia (BPH), announces new private ownership and is ... medical device industry veteran of more than 20 years, ... Plymouth, Minn. The ... and Prostiva® RF Therapy, will continue to be broadly ...
(Date:2/10/2016)... 2016 Immune Pharmaceuticals Inc. (NASDAQ: IMNP ... it has filed a patent application directed to the ... --> --> The new ... Ceplene (histamine dihydrochloride) in combination with immune checkpoint inhibitors. ... efficacy of Ceplene and IL-2 therapy in patients with ...
(Date:2/10/2016)... Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC Markets: ... 1-for-100 reverse split of its issued and outstanding shares ... on Thursday, February 11, 2016. The Company,s common stock ... number 76303T308 and temporary ticker symbol "RCHAD". After 20 ... the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: